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118
We report a case of Paget's disease of the skull and maxilla in a patient who 121  122  123  124  125  126  127  128  129  130  131  132  133 Symptomatic PD is the main indication for treatment (pain, nerve compression…)
311
[1].
312
Treatment aims at the suppression of osteoclast activity and is achieved with 313 bisphosphonates.
314
The optimal regimen of BPs remains controversial. Oral formulations may be 315 limited by complicated dosing regimens and poor gastrointestinal absorption. 
319
Medication related osteonecrosis of the jaw is defined as an exposed bone or bone 320 that can be probed through an intraoral or extraoral fistula in the maxillofacial 
325
The exact mechanism of MRONJ remains unclear. Alteration of bone turnover,
326
hypovascularisation and infection seem to play a role. The majority of MRONJ are 327 in relation with tooth extraction.
328
The real incidence of MRONJ is still unknown and varies between 1,2% and 12,8% 329 in cancer patients. In a report of Mavrokokki [13] , the overall incidence of MRONJ 
344
Even sequestration can be an exceptional but normal complication in PD, treatment
345
with BPs may be the trigger factor of the osteonecrosis. In our patient, the first 346 episode of bone necrosis appeared after oral surgery and repeated doses of iv BP.
